TerminatedPhase 2NCT00211471

Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).

Studying Central retinal vein occlusion

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Manhattan Eye, Ear & Throat Hospital
Principal Investigator
Lawrence A. Yannuzzi, MD
Manhattan Eye, Ear & Throat Hospital
Intervention
anecortave acetate(drug)
Eligibility
18 years · All sexes
Timeline
20022007

Study locations (1)

Collaborators

Alcon Research

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00211471 on ClinicalTrials.gov

Other trials for Central retinal vein occlusion

Additional recruiting or active studies for the same condition.

See all trials for Central retinal vein occlusion

← Back to all trials